1. Cancer cells under immune attack acquire CD47-mediated adaptive immune resistance independent of the myeloid CD47-SIRP alpha axis
- Author
-
Isabel Britsch, Mark A. J. M. Hendriks, Anne P. van Wijngarden, Douwe F. Samplonius, Xiurong Ke, Wijnand Helfrich, Emily M. Ploeg, Targeted Gynaecologic Oncology (TARGON), and Translational Immunology Groningen (TRIGR)
- Subjects
T cell-induced cytotoxicity ,Myeloid ,MONOCLONAL-ANTIBODY ,T cell ,medicine.medical_treatment ,T-Lymphocytes ,Immunology ,Cell ,PROTEIN ,CD47 Antigen ,Biology ,resistance ,Immune system ,Cancer immunotherapy ,Neoplasms ,Antibodies, Bispecific ,medicine ,Immunology and Allergy ,Humans ,CD47 ,RC254-282 ,FRAGMENT ,cancer immunotherapy ,Cancer ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC581-607 ,medicine.disease ,bispecific antibody ,medicine.anatomical_structure ,Oncology ,CD47 INDUCES APOPTOSIS ,Cancer cell ,Cancer research ,Immunotherapy ,Immunologic diseases. Allergy ,Research Article - Abstract
Cancer cells exploit CD47 overexpression to inhibit phagocytic elimination and neoantigen processing via the myeloid CD47-SIRP alpha axis and thereby indirectly evade adaptive T cell immunity. Here, we report on a hitherto unrecognized direct immunoinhibitory feature of cancer cell-expressed CD47. We uncovered that in response to IFN gamma released during cognate T cell immune attack, cancer cells dynamically enhance CD47 cell surface expression, which coincides with acquiring adaptive immune resistance toward pro-apoptotic effector T cell mechanisms. Indeed, CRISPR/Cas9-mediated CD47-knockout rendered cancer cells more sensitive to cognate T cell immune attack. Subsequently, we developed a cancer-directed strategy to selectively overcome CD47-mediated adaptive immune resistance using bispecific antibody (bsAb) CD47xEGFR-IgG2s that was engineered to induce rapid and prolonged cancer cell surface displacement of CD47 by internalization. Treatment of CD47(pos) cancer cells with bsAb CD47xEGFR-IgG2s potently enhanced susceptibility to cognate CD8(pos) T cells. Targeting CD47-mediated adaptive immune resistance may open up new avenues in cancer immunotherapy.
- Published
- 2021